Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alkotinib - Suzhou Zelgen Biopharmaceuticals

Next Previous
Search
Drug Profile

Alkotinib - Suzhou Zelgen Biopharmaceuticals

Alternative Names: Ocatinib; ZG0418

Latest Information Update: 07 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Zelgen Biopharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 26 Apr 2024 Suzhou Zelgen Biopharmaceuticals terminates a phase II trial in in Non-small cell lung cancer (Second-line therapy or greater) in China (PO) (NCT04211922)
  • 28 Nov 2022 Phase II trial is still ongoing for Non-small cell lung cancer (Second-line therapy or greater) in China (PO) (NCT04211922)
  • 17 Oct 2022 Suzhou Zelgen Biopharmaceuticals completes a phase I trial in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, In adults, In the elderly, Late-stage disease) in China (PO) (NCT03607188)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top